JP
Therapeutic Areas
Galmed Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Aramchol Meglumine | NASH and Fibrosis | Phase 3 |
| Amilo-5MER | Inflammatory Diseases | Preclinical |
Leadership Team at Galmed Pharmaceuticals
AB
Allen Baharaff
Chief Executive Officer & President
DC
Doron Cohen
Chief Financial Officer
LH
Liat Hayardeny - Brueck, Ph.D.
Chief Scientific Officer
GN
Guy Nehemya, Adv.
Chief Operating Officer
YS
Yohai Stenzler, CPA
Chief Accounting Officer
YG
Yossi Gilgun-Sherki, Ph.D.
Executive Clinical Consultant
TG
Tali Gorfine, M.D.
Executive Clinical Development Consultant
SE
Shaul E. Kadosh
Biostatistical & Clinical Research Consultant
JK
Joseph Kaspi, Ph.D.
Senior CMC Director (Consultant)
DM
Dalia Medini, Ph.D.
Analytical Advisor (Consultant)